Daclatasvir
Cat. No.：YN250108
CAS No. ：1009119-64-5
| 产品名称: | Daclatasvir |
| CAS No.: | 1009119-64-5 |
| Chemical Name: | N,N'-[[1,1'-biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-carbamic acid, C,C'-dimethyl ester |
| Synonyms: | 达拉他韦; BMS-790052; EBP 883 |
| 分子量: | 738.88 |
| 分子式: | C₄₀H₅₀N₈O₆ |
| SMILES: | O=C([C@@H](NC(OC)=O)C(C)C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C5=CN=C([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)N5)C=C4 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Daclatasvir (BMS-790052) 是一种有效的口服活性HCV NS5A蛋白抑制剂，多种HCV复制子基因型的EC50范围为 9-146 pM。Daclatasvir 也是有机阴离子转运多肽 1B (OATP1B) 和OATP1B3抑制剂，IC50分别为 1.5 µM 和 3.27 µM。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Gao, M., Nettles, R.E., Belema, M., et al.Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectNature465(7294),96-100(2010)
Ascher, D.B., Wielens, J., Nero, T.L., et al.Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNASci. Rep.4,4765(2014)
Lee, C., Ma, H., Hang, J.Q., et al.The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral proteinVirology414(1),10-18(2011)
Guedj, J., Dahari, H., Rong, L., et al.Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeProc. Natl. Acad. Sci. USA110(10),3991-3996(2013)
Furihata, T., Matsumoto, S., Fu, Z., et al.Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptidesAntimicrob. Agents Chemother.58(8),4555-4565(2014)
